Ivan Gergel becomes SVP, Drug Development & Chief Medical Officer at Nektar Therapeutics

Joins the company from Endo Pharmaceuticals

Nektar Therapeutics, a biopharmaceutical company developing novel pain and cancer therapeutics, has appointed Ivan Gergel as Senior Vice President, Drug Development & Chief Medical Officer. Gergel will have responsibility for the company's clinical strategy and activities, including direct supervision of clinical research, clinical operations, medical affairs, regulatory affairs, and drug safety and surveillance.

Gergel brings more than 25 years of pharmaceutical leadership and drug development experience to Nektar. From 2008 to 2014 he was Executive Vice President, Research & Development of Endo Pharmaceuticals and Chief Scientific Officer.

Prior to joining Endo, he was Senior Vice President of Research and Development at Forest Laboratories. Before this he was a senior leader at SmithKline Beecham where he was in charge of the US clinical team responsible for the development and commercial support of Paxil, which is approved to treat depression, OCD, panic disorder, social phobia and generalized anxiety disorder.

Robert Medve, Nektar's former Senior Vice President and Chief Medical Officer, left the company on 16 May.

You may also like

Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Distribution

Tower Cold Chain launches live tracking and monitoring for pharmaceutical distribution

The upgrade allows customers to access real-time insights into shipments, facilitating the optimisation of cold chain processes
Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Manufacturing

The US pharmaceutical landscape: growth, innovation and challenges ahead

The US pharmaceutical market is one of the largest in the world and is experiencing healthy growth owing to its ageing population, the willingness of consumers to spend on healthcare and a high level of investment in R&D, the results of which receive strong intellectual property protection
Subscribe now